China-based vaccines specialist CanSino Biotechnology Inc., (HKG: 6185) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its adsorbed tetanus vaccine, CS-2047, aimed at preventing tetanus in adults.
Emphasis on Tetanus Prevention in Adult Immunization
The National Health Commission (NHC) has previously released the “Diagnostic and Treatment Guidelines for Non-Newborn Tetanus (2019 Edition),” which underscores the importance of major immunization efforts with tetanus toxoid vaccines. These vaccines play a critical role in the prevention of non-newborn tetanus, and the approval of CS-2047 marks a significant step forward in this regard.
Safety and Industrialization of CS-2047
CS-2047 is fermented in an animal-free culture medium, ensuring safety and a determined industrialization scale process with stable manufacturing procedures. The vaccine is primarily intended for non-neonatal tetanus prevention, offering a new option for adult immunization against this serious bacterial infection.-Fineline Info & Tech
